Clinical Oncology
Volume 19, Issue 1 , Pages 63-70 , February 2007

Functional and Pharmacokinetic Outcomes after a Single Intravenous Infusion of Recombinant Human Erythropoietin in Patients with Malignant Extradural Spinal Cord Compression

  • D.A. Loblaw

      Affiliations

    • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationAuthor for correspondence: D. A. Loblaw, Department of Radiation Oncology, Sunnybrook and Women's College Health Sciences Centre, T2-107, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. Tel: +1-416-480-4806; Fax: +1-416-480-6002.
    • ,
  • L. Holden

      Affiliations

    • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • ,
  • A. Xenocostas

      Affiliations

    • Division of Hematology, London Health Science Center, University of Western Ontario, London, Ontario, Canada
    • ,
  • E. Chen

      Affiliations

    • Department of Medical Oncology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada
    • ,
  • S. Chander

      Affiliations

    • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • ,
  • P. Cooper

      Affiliations

    • Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • ,
  • P.C. Chan

      Affiliations

    • Department of Clinical Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • ,
  • C.S. Wong

      Affiliations

    • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Received 2 March 2006 ,Revised 5 October 2006 ,Accepted 23 October 2006.

References 

  1. Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario. Clin Oncol. 2003;15(4):211–217
  2. Loblaw DA, Laperiere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol. 1998;16(4):1613–1624
  3. Kim RY, Spencer SA. Extradural spinal cord compression: analysis of factors determining functional prognosis – prospective study. Radiol. 1990;176:279–282
  4. Helwig-Larsen S, Sorensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influenceing survival and gait function in 153 patients. Int J Rad Oncol Biol Phys. 2000;46(5):1163–1169
  5. Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia. 2000;30(3):271–278
  6. Brines ML, Ghezzi P, Keenan S, et al. Erythropoetin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526–10531
  7. Lipton SA. Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med. 2004;350(24):2516–2517
  8. Littlewood TJ, Bajetta E, Nortier JWR, Varcammen E, Rapoport B. for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865–2874
  9. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19(21):4126–4134
  10. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. PNAS. 2002;99(4):2258–2263
  11. Ehrenreich H, Hasselblatt M, Piotr L, et al. Erythropoetin treatment for acute stroke: a randomized double-blind proof-of-concept trial in man. Stroke. 2001;33(1):324
  12. Colton T. Statistics in Medicine. Boston: Little, Brown and Company; 1974;
  13. Rades D, Heidenreich F, Karstens JH. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2002;53:975–979
  14. Reiber H. The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid. J Neurol. 1980;224:89–99
  15. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol. 2002;64(3):275–280
  16. Mitera G, Loblaw DA. Delays from symptom onset to treatment in malignant spinal cord compression: quantification and effect on pre-treatment neurological status. Proc Amer Soc Clin Oncol. 2004;23:119;(abstract 8276)
  17. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol. 2005;61(3):189–195
  18. Rades D, Karstens JH, Alberti W. Role of radiotherapy in the treatment of motor dysfunction due to metastatic spinal cord compression: comprarison of three different fractionation schedules. Int J Rad Onc Biol Phys. 2002;54(4):1160–1164
  19. Loblaw DA, Laperriere NJ. The Princess Margaret Hospital Experience of malignant spinal cord compression. Proc Amer Soc Clin Oncol. 2003;22:119;(abstract 477)
  20. Woolf SH, Battista RN, Anderson GM, et al. Assessing the clinical effectiveness of preventative maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epi. 1990;43(9):891–905
  21. Woolf SH, Haggerty J. A systematic methodology for reviewing the evidence. Checklists for task force reviews. Toronto: Canadian Task Force on the Periodic Health Examiniation; 1988;
  22. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028–2037
  23. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886
  24. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892
  25. Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Ann Neurol. 1991;3:40–51
  26. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. International Journal of Radiation Oncology, Biology, Physics. 1995;32(4):959–967
  27. Helweg-Larsen . Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand. 1996;94:264–275
  28. Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. American Journal of Clinical Oncology. 1996;19(2):179–183
  29. Maranzano E, Latini P, Beneventi S, et al. Comparison of two different kinds of radiotherapy schedules for spinal cord compression. Tumori. 1998;84:472–477
  30. Kovner F, Spigel S, Rider I, et al. Radiation therapy of metastatic spinal cord compression. J Neuroonc. 1999;42:85–92
  31. Patchell R, Tibbs PA, Regine WF, et al. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastases. Proc ASCO. 2003;22:1;(abstract 2)
  32. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin Regulates the In Vitro and In Vivo Production of Neuronal Progenitors by Mammalian Forebrain Neural Stem Cells. The Journal of Neuroscience. 2001;21(4):9733–9743
  33. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921–926
  34. Anagnostou A, Lee ES, Kessimian N, R Levinson MSteiner. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87(15):5978–5982
  35. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340–1346
  36. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9(Suppl 5):18–30
  37. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97(7):489–498

PII: S0936-6555(06)00410-9

doi: 10.1016/j.clon.2006.10.009

Clinical Oncology
Volume 19, Issue 1 , Pages 63-70 , February 2007

Article Tools